Fig. 3.

Forest plot showing the sensitivity, specificity, and log (DOR) of CEUS for identifying residual HCC tumors after ablation (A) or TACE (B). The enhancement criteria for identifying residual tumors were APHE only or any other enhancement criteria (including hypo and/or iso-enhancement). Pooled sensitivities, specificities, and log (DOR) were not significantly different between studies using APHE or studies using any other enhancement criteria. APHE arterial phase hyperenhancement, CEUS contrast-enhanced ultrasound, DOR diagnostic odds ratio, TACE transarterial chemoembolization